NTRK gene fusion testing and management in lung cancer.
Date
2024-06-01ICR Author
Author
Repetto, M
Chiara Garassino, M
Loong, HH
Lopez-Rios, F
Mok, T
Peters, S
Planchard, D
Popat, S
Rudzinski, ER
Drilon, A
Zhou, C
Type
Journal Article
Metadata
Show full item recordAbstract
Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are recurrent oncogenic drivers found in a variety of solid tumours, including lung cancer. Several tropomyosin receptor kinase (TRK) inhibitors have been developed to treat tumours with NTRK gene fusions. Larotrectinib and entrectinib are first-generation TRK inhibitors that have demonstrated efficacy in patients with TRK fusion lung cancers. Genomic testing is recommended for all patients with metastatic non-small cell lung cancer for optimal drug therapy selection. Multiple testing methods can be employed to identify NTRK gene fusions in the clinic and each has its own advantages and limitations. Among these assays, RNA-based next-generation sequencing (NGS) can be considered a gold standard for detecting NTRK gene fusions; however, several alternatives with minimally acceptable sensitivity and specificity are also available in areas where widespread access to NGS is unfeasible. This review highlights the importance of testing for NTRK gene fusions in lung cancer, ideally using the gold-standard method of RNA-based NGS, the various assays that are available, and treatment algorithms for patients.
Collections
Subject
Lung cancer
NTRK gene fusion
TRK fusion
Humans
Lung Neoplasms
Receptor, trkA
Gene Fusion
Carcinoma, Non-Small-Cell Lung
Oncogene Proteins, Fusion
High-Throughput Nucleotide Sequencing
Protein Kinase Inhibitors
Receptor, trkB
Language
eng
Date accepted
2024-04-02
License start date
2024-06-01
Citation
Cancer Treatment Reviews, 2024, 127 pp. 102733 -
Publisher
ELSEVIER SCI LTD
Except where otherwise noted, this item's license is described
as
http://creativecommons.org/licenses/by/4.0/
Related items
Showing items related by title, author, creator and subject.
-
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.
Demetri, GD; Antonescu, CR; Bjerkehagen, B; Bovée, JVMG; Boye, K; et al. (2020-11)Sarcomas are a heterogeneous group of malignancies with mesenchymal lineage differentiation. The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions as tissue-agnostic oncogenic drivers has led to new ... -
BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer.
Li, X; Baek, G; Ramanand, SG; Sharp, A; Gao, Y; et al. (CELL PRESS, 2018-01-16)BRD4 belongs to the bromodomain and extraterminal (BET) family of chromatin reader proteins that bind acetylated histones and regulate gene expression. Pharmacological inhibition of BRD4 by BET inhibitors (BETi) has indicated ... -
A causal mechanism for childhood acute lymphoblastic leukaemia.
Greaves, M (NATURE PORTFOLIO, 2018-08-01)In this Review, I present evidence supporting a multifactorial causation of childhood acute lymphoblastic leukaemia (ALL), a major subtype of paediatric cancer. ALL evolves in two discrete steps. First, in utero initiation ...